Jack Snitzer, DO
Endocrinology, Diabetes & Metabolism · Salisbury, MDNPI 1033152103
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $31,473 of the $39,533 with a category attached, or 79.6%. Dexcom, Inc. accounts for 74.3% of it on its own, with 32 other manufacturers making up the rest. Among endocrinology, diabetes & metabolism clinicians in MD with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 228 payments — averaging $173.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Dexcom, Inc.$29K
- Abbott$7K
- Lilly USA, LLC$391
- Insulet Corporation$334
- Medtronic$255
- Tandem Diabetes Care, Inc.$246
- plus $2K from 27 others
What the payments were for
- Consulting fees$2,5576%
- Speaking & faculty fees$31,47380%
- Travel & lodging$1,0003%
- Food & beverage$4,48011%
- Education$240%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Dexcom, Inc. | 71 | $29,376 |
| Abbott | 26 | $7,372 |
| Lilly USA, LLC | 21 | $391 |
| Insulet Corporation | 13 | $334 |
| Medtronic(2 entities) | 7 | $255 |
| Tandem Diabetes Care, Inc. | 8 | $246 |
| Amgen(2 entities) | 11 | $232 |
| Novo Nordisk | 11 | $206 |
| Johnson & Johnson | 5 | $96 |
| Sanofi-aventis U.S. LLC | 5 | $93 |
| AstraZeneca(2 entities) | 5 | $84 |
| Cequr Corporation | 2 | $81 |
| Xeris Pharmaceuticals, Inc. | 4 | $77 |
| Sequel Med Tech, LLC | 3 | $70 |
| AbbVie | 4 | $58 |
| Amneal Pharmaceuticals LLC | 3 | $52 |
| Merck | 4 | $50 |
| Shire North American Group Inc | 2 | $47 |
| Radius Health, Inc. | 2 | $47 |
| Soleno Therapeutics, Inc. | 2 | $43 |
| BD | 2 | $40 |
| Companion Medical, Inc. | 3 | $37 |
| Corcept Therapeutics | 2 | $36 |
| Valeritas, Inc. | 2 | $35 |
| BETA Bionics, Inc. | 2 | $26 |
| Ascendis Pharma Endocrinology Inc | 1 | $26 |
| Kyowa Kirin, Inc. | 1 | $23 |
| Averitas Pharma Inc. | 1 | $23 |
| Recordati_rare_diseases_inc. | 1 | $17 |
| Boehringer Ingelheim | 1 | $15 |
| Acella Pharmaceuticals, LLC | 1 | $14 |
| Amarin Pharma, Inc. | 1 | $14 |
| Siemens Medical Solutions USA, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DEXCOM G7 GSS (161)$20,054
- DEXCOM G6 TRANSMITTER$8,378
- DEXCOM STELO GLUCOSE BIOSENSOR$6,622
- FreeStyle Libre Pro$4,888
- FreeStyle Libre 2$1,835
- FreeStyle Libre$450
- MINIMED 780G$103
How this compares
$39,533 in reported general payments places this provider in the 90th percentile of 235 endocrinology, diabetes & metabolism providers in Maryland.
See all endocrinology, diabetes & metabolism providers in Maryland →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 272 | $506,153 |
| TrulicityDulaglutide | 129 | $224,411 |
| MounjaroTirzepatide | 116 | $174,421 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 83 | $129,005 |
| JardianceEmpagliflozin | 109 | $114,887 |
| JanuviaSitagliptin Phosphate | 91 | $95,879 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 167 | $72,392 |
| RybelsusSemaglutide | 35 | $64,467 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 50 | $60,170 |
| Tresiba Flextouch U-200Insulin Degludec | 47 | $56,551 |
| FarxigaDapagliflozin Propanediol | 38 | $45,210 |
| Humalog Kwikpen U-100Insulin Lispro | 139 | $42,357 |
| Humalog Kwikpen U-200Insulin Lispro | 15 | $37,918 |
| Tresiba Flextouch U-100Insulin Degludec | 52 | $37,767 |
| Admelog SolostarInsulin Lispro | 89 | $36,145 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Novolog | $206 | $596,626380 claims |
| Lilly USA, LLCTrulicity, Mounjaro, Humalog | $391 | $422,347306 claims |
| Boehringer IngelheimJardiance, Tradjenta | $15 | $130,081124 claims |
| MerckJanuvia | $50 | $95,87991 claims |
| AstraZenecaFarxiga | $84 | $45,21038 claims |
| AbbVieSynthroid | $58 | $32,987338 claims |
| Sanofi-aventis U.S. LLCAdmelog, Lantus | $93 | $31,07671 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $52 | $8,487836 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 235 endocrinology, diabetes & metabolism providers in Maryland.
Other endocrinology, diabetes & metabolism in Salisbury
- Daniel GozziSuitland$1.2M
- Martin SarkarFrederick$1.1M
- Nicholas ArgentoLaurel$1.1M
- Romeu AzevedoCamp Springs$987K
- David BrownRockville$497K
- Philip LevinBaltimore$489K
- Helena RodbardRockville$468K
- Roy PhillipsBel Air$208K
- Eyob MakonnenAnnapolis$205K
- Jawaad KhokharGlen Burnie$155K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.